Pulmatrix Inc (PULM)

$5.14 -0.17 (-3.20%)
Market Cap 20.00M
Revenue (ttm) 7.81M
Net Income (ttm) -6.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -88.86%
Debt to Equity Ratio 0.00
Volume 9,778
Avg Vol 35,662
Day's Range N/A - N/A
Shares Out 3.65M
Stochastic %K 30%
Beta 1.45
Analysts Strong Buy
Price Target $10.00

Company Profile

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clin...

Industry: Biotechnology
Sector: Healthcare
Phone: (888) 355-4440
Address:
945 Concord Street, Suite 1217, Framingham, United States
Igotzthis
Igotzthis Aug. 7 at 7:42 PM
$PULM well, is everyone ready for merger Monday. I know I am. Super bullish.
0 · Reply
madan_shatri
madan_shatri Aug. 7 at 6:59 PM
$PULM hahaha clown says assets have already been sold for $120M wow ! Let me demolish that joker. So someone spent this much of money to buy PULM assets when they struggled for pennies all these 10 years ? Couldn't even get decent royalty based deal with Cipla and you are talking about $120 million ? So lets for argument sake assuming someone has already bought PULM assets, then if the buyer is a publically listed company then how long can the buyer be silent ? Why would someone accept an NDA when spending $100+ million and agreeing on not to PR to their SHs ? So $100+ million is spent with precondition that announcement will only happen after PULM - Cullgen deal completes ? I have seen circuses many times but a clown like this is unique !
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 7 at 5:09 PM
$PULM business dynamics have shifted reasonably
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 7 at 5:07 PM
$PULM letter has been delivered signed sealed very good
1 · Reply
Igotzthis
Igotzthis Aug. 6 at 4:43 PM
$PULM Save this post and repost after September 30th. PULMATRIX WILL EASILY SELL ALL ASSETS FOR OVER 120 Million. JMO!!!
2 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Aug. 6 at 1:20 PM
$PULM almost time
1 · Reply
hippo_hungry
hippo_hungry Aug. 6 at 12:50 PM
$PULM 😂 a lot of smoke 💨 and mirrors in that filing ..
1 · Reply
ony2k
ony2k Aug. 6 at 4:24 AM
$PULM Hello all. Looking in not often enough these days in my book Im proud to say the investment remains intact, same as before, except for the ones I added when deitrickdickAF or something like that wasn't looking. Shoot me for forgetting the names during the years. All I know is all of em end with AF, as if the guy is excited and As Fuck about it, but cant say it.....who knows. Maybe its about the new name he thought up. It sure is nice seeing some familiar bullish faces from the past, of which, cant be a bad thing when you think about it. Something tells me they....hmmmmm. Dangit, Here I go again, about to set you know off again for saying what I think about me think'in they know too. Poor guy. I think I got him with that last sentence. Who knows. Maybe he'll get to scratching his head so hard over it it'll cave in.
0 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Aug. 5 at 6:44 PM
$PULM
0 · Reply
Igotzthis
Igotzthis Aug. 5 at 3:01 PM
$PULM So Vertex Pharmaceuticals pain drug just failed in phase 2 trials. This could open the door for Cullgens CG001419 Acute and Chronic Pain drug to replace opioids. This is going to be huge.
0 · Reply
Latest News on PULM
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

Aug 6, 2025, 8:05 AM EDT - 1 day ago

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 15, 2025, 8:05 AM EDT - 3 months ago

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

May 9, 2025, 4:00 PM EDT - 3 months ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Mar 21, 2025, 8:05 AM EDT - 4 months ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

Nov 15, 2024, 8:00 AM EST - 9 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

ENTO

Pulmatrix and Cullgen Announce Proposed Merger

Nov 13, 2024, 9:00 AM EST - 9 months ago

Pulmatrix and Cullgen Announce Proposed Merger

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 10:26 AM EST - 9 months ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

May 29, 2024, 8:45 AM EDT - 1 year ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MNKD

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 15, 2024, 9:35 AM EDT - 1 year ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 10, 2024, 8:05 AM EDT - 1 year ago

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Jan 8, 2024, 9:00 AM EST - 1 year ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 9:05 AM EST - 1 year ago

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Sep 19, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Aug 23, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Jul 11, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

Jun 15, 2023, 9:20 AM EDT - 2 years ago

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 24, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

Pulmatrix Supports World Asthma Day 2023

May 2, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Supports World Asthma Day 2023

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Mar 30, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Feb 6, 2023, 9:10 AM EST - 2 years ago

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Jan 25, 2023, 9:05 AM EST - 2 years ago

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Jan 23, 2023, 9:05 AM EST - 2 years ago

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Jan 4, 2023, 9:05 AM EST - 2 years ago

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 10, 2022, 9:05 AM EST - 2 years ago

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Sep 26, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 8, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Jul 12, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 12, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Mar 29, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Mar 21, 2022, 12:45 PM EDT - 3 years ago

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Mar 21, 2022, 8:05 AM EDT - 3 years ago

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Mar 17, 2022, 4:05 PM EDT - 3 years ago

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Mar 1, 2022, 9:00 AM EST - 3 years ago

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Feb 24, 2022, 4:05 PM EST - 3 years ago

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Pulmatrix Issues Letter to Stockholders

Feb 1, 2022, 9:00 AM EST - 3 years ago

Pulmatrix Issues Letter to Stockholders

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Dec 17, 2021, 4:30 PM EST - 3 years ago

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Pulmatrix Announces $6.75 Million Registered Direct Offering

Dec 15, 2021, 8:00 AM EST - 3 years ago

Pulmatrix Announces $6.75 Million Registered Direct Offering

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 10, 2021, 4:15 PM EST - 4 years ago

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

Pulmatrix Announces Resolution of Contract Dispute with Cipla

Nov 9, 2021, 9:00 AM EST - 4 years ago

Pulmatrix Announces Resolution of Contract Dispute with Cipla

Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update

Aug 10, 2021, 9:10 AM EDT - 4 years ago

Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update

Pulmatrix appoints Director Anand Varadan

Jul 27, 2021, 10:00 AM EDT - 4 years ago

Pulmatrix appoints Director Anand Varadan

Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update

May 11, 2021, 4:35 PM EDT - 4 years ago

Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update

Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine

Apr 15, 2021, 9:15 AM EDT - 4 years ago

Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine

Igotzthis
Igotzthis Aug. 7 at 7:42 PM
$PULM well, is everyone ready for merger Monday. I know I am. Super bullish.
0 · Reply
madan_shatri
madan_shatri Aug. 7 at 6:59 PM
$PULM hahaha clown says assets have already been sold for $120M wow ! Let me demolish that joker. So someone spent this much of money to buy PULM assets when they struggled for pennies all these 10 years ? Couldn't even get decent royalty based deal with Cipla and you are talking about $120 million ? So lets for argument sake assuming someone has already bought PULM assets, then if the buyer is a publically listed company then how long can the buyer be silent ? Why would someone accept an NDA when spending $100+ million and agreeing on not to PR to their SHs ? So $100+ million is spent with precondition that announcement will only happen after PULM - Cullgen deal completes ? I have seen circuses many times but a clown like this is unique !
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 7 at 5:09 PM
$PULM business dynamics have shifted reasonably
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 7 at 5:07 PM
$PULM letter has been delivered signed sealed very good
1 · Reply
Igotzthis
Igotzthis Aug. 6 at 4:43 PM
$PULM Save this post and repost after September 30th. PULMATRIX WILL EASILY SELL ALL ASSETS FOR OVER 120 Million. JMO!!!
2 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Aug. 6 at 1:20 PM
$PULM almost time
1 · Reply
hippo_hungry
hippo_hungry Aug. 6 at 12:50 PM
$PULM 😂 a lot of smoke 💨 and mirrors in that filing ..
1 · Reply
ony2k
ony2k Aug. 6 at 4:24 AM
$PULM Hello all. Looking in not often enough these days in my book Im proud to say the investment remains intact, same as before, except for the ones I added when deitrickdickAF or something like that wasn't looking. Shoot me for forgetting the names during the years. All I know is all of em end with AF, as if the guy is excited and As Fuck about it, but cant say it.....who knows. Maybe its about the new name he thought up. It sure is nice seeing some familiar bullish faces from the past, of which, cant be a bad thing when you think about it. Something tells me they....hmmmmm. Dangit, Here I go again, about to set you know off again for saying what I think about me think'in they know too. Poor guy. I think I got him with that last sentence. Who knows. Maybe he'll get to scratching his head so hard over it it'll cave in.
0 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Aug. 5 at 6:44 PM
$PULM
0 · Reply
Igotzthis
Igotzthis Aug. 5 at 3:01 PM
$PULM So Vertex Pharmaceuticals pain drug just failed in phase 2 trials. This could open the door for Cullgens CG001419 Acute and Chronic Pain drug to replace opioids. This is going to be huge.
0 · Reply
Igotzthis
Igotzthis Aug. 5 at 2:37 PM
$PULM awful quiet out there. Hearing a lot of crickets. With that said I’m bringing sexy back and merger Monday. It’s a B1G1F. Or maybe we should call it 2 for Tuesday. 😂😂😂
1 · Reply
Igotzthis
Igotzthis Aug. 4 at 6:04 PM
$PULM So merger Monday is not really working out. Need to broaden it a little bit. Changing it too Merger August!!! But I’m still going with I’m bringing sexy back!!! 🤣🤣🤣
0 · Reply
madan_shatri
madan_shatri Aug. 2 at 8:16 AM
$PULM https://asia.nikkei.com/Politics/International-relations/US-China-tensions/China-pauses-US-bound-company-investment-amid-trade-war Can this be the reason behind delay ?
1 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 9:58 PM
$ADIL thats quite interesting $PSTV enter $PULM seems u cooking something u know batman and robin? i told the akebiens aboiut it as well ! any long on pulm recall batman and robin its as theme this weekend for next week market wise
0 · Reply
Freetimeod
Freetimeod Aug. 1 at 6:59 PM
$PULM people just sick of the never ending games these a$$WIPES play. “Oh we’re going to do this” and then it never comes to fruition?
1 · Reply
Igotzthis
Igotzthis Aug. 1 at 6:19 PM
$PULM I’m bringing sexy back and also merger Monday. So hang on tight and enjoy the weekend. And remember keep the faith!!!
1 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Aug. 1 at 12:40 PM
$PULM how bout a jump?
0 · Reply
hippo_hungry
hippo_hungry Jul. 31 at 4:12 PM
$PULM wen rug pull
1 · Reply
Pilot288
Pilot288 Jul. 31 at 2:33 PM
$PULM what time is Merger Thursday supposed to start? Asking for a friend…
1 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Jul. 31 at 1:19 PM
$PULM
0 · Reply
Igotzthis
Igotzthis Jul. 30 at 7:23 PM
$PULM Tomorrow is merger Thursday. Hang on to your hats everyone its going to be a wild ride. Oh yeah!!!
1 · Reply
HFH_Inc
HFH_Inc Jul. 30 at 5:08 PM
$PULM I have mostly exited here and did so several months ago. Couldn't wait any longer. Got just a few shares left in one account. Wanted to stay quiet, while I was focused and parked my money in Top 10 crypto coins. Told a few of you here about this move. So far satisfied with this move. Had to leave while the getting was good. This did get to $10 which I had stated to a few here as my realistic goal for this. I am fully out of biotech forever, besides a few shares I have left here in one account. Good luck to everyone here. Even the Madan "Focker" Shatri. Definitely made a few friends over the years. And a few enemies... I am holding strong in $BTC $ETH $XRP $AVAX $LTC $ADA $SOL . Looking for 3X in next year or so. Already doubled on some. Anyway, how we are loving this guy?! Been an absolute joy so far, after that 💩 show Biden....and the drunk Kamala.
1 · Reply